Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BJ6 + hypromellose is a combination of two agents used as artificial tear substitutes for the symptomatic relief of dry eye conditions such as keratoconjunctivitis sicca. Hypromellose (also known as hydroxypropyl methylcellulose) is a synthetic polymer that acts as an ocular lubricant and protectant, helping to maintain moisture on the ocular surface and reduce irritation caused by reduced tear flow. The precise identity and mechanism of "BJ6" are not clearly defined in available literature; however, it appears to be a component or formulation used in clinical trials for dry eye treatment alongside or compared with hypromellose[1]. Both components function primarily by providing lubrication and mimicking natural tears to alleviate symptoms like dryness, burning, itching, and discomfort associated with dry eyes[2][3][4]. This combination does not have evidence of additional pharmacological activity beyond lubrication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BJ6 + hypromellose.